Q32 Bio receives Nasdaq delisting notice for stockholders' equity deficiency

Q32 Bio Inc.

Stockholders' equity (deficit) of ~($4.0M) as of March 31, 2025, below Nasdaq's $2.5M minimum.
Also failed market value ($35M) and net income ($0.5M) alternatives.
Company has 45 calendar days to submit a plan to regain compliance; Nasdaq may grant up to 180 days.
Bempikibart-related liability of $55M from Amgen re-acquisition contributes to deficit.
No immediate effect on listing; stock continues trading under QTTB.

item 3.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.